Literature DB >> 9687980

Theoretical treatment of human haemopoietic stem cell survival following irradiation by alpha particles.

D E Charlton1, T D Utteridge, B J Allen.   

Abstract

PURPOSE: To calculate survival of human haemopoietic stem cells irradiated by alpha particles from 149Tb (initial energy 3.97 MeV) and 211At (average initial energy 6.87 MeV).
METHODS: Following as closely as possible radiobiological data, Monte Carlo methods were used to calculate passages of alpha particles (originating in three geometries) through the nuclei of haemopoietic stem cells. Survival of stem cell populations was calculated from the probability of surviving each passage (a function of LET).
RESULTS: For decays targeted to the surface of individual cells 37% survival was found at 1.3 passages per nucleus for 149Tb and 6.5 for 211At/Po decays. For decays distributed in a large volume the D0 doses were 0.81 and 0.87 for 149Tb and 211At respectively. When 36% of the marrow is occupied by fat cells alphas from 149Tb are more effective with a D0 of 0.68Gy compared to 0.82Gy for the 211At/Po combination.
CONCLUSIONS: When the isotopes are targeted to the cell, in terms of passages, 149Tb is five times more effective at cell killing than 211At, which when expressed in terms of dose, increases to a factor of 9. When the isotopes are broadly distributed (such as in marrow or in vitro) the differences are considerably reduced.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687980     DOI: 10.1080/095530098141771

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  4 in total

Review 1.  Modelling and dosimetry for alpha-particle therapy.

Authors:  George Sgouros; Robert F Hobbs; Hong Song
Journal:  Curr Radiopharm       Date:  2011-07

2.  Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with 223Ra: The Role of Bystander Effects and Their Potential for Therapy.

Authors:  Calvin N Leung; Brian S Canter; Didier Rajon; Tom A Bäck; J Christopher Fritton; Edouard I Azzam; Roger W Howell
Journal:  J Nucl Med       Date:  2019-09-13       Impact factor: 10.057

3.  MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Authors:  George Sgouros; John C Roeske; Michael R McDevitt; Stig Palm; Barry J Allen; Darrell R Fisher; A Bertrand Brill; Hong Song; Roger W Howell; Gamal Akabani; Wesley E Bolch; A Bertrand Brill; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels; Pat B Zanzonico
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

4.  Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab.

Authors:  G-J Beyer; M Miederer; S Vranjes-Durić; J J Comor; G Künzi; O Hartley; R Senekowitsch-Schmidtke; D Soloviev; F Buchegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.